Drug shortage
Sodium Acetate Injection · Hospira, Inc., a Pfizer Company
FDA drug shortage · Current · updated Apr 11, 2025
Key facts
| Generic name | Sodium Acetate Injection |
|---|---|
| Proprietary name | Sodium Acetate |
| Company | Hospira, Inc., a Pfizer Company |
| Presentation | Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-25) |
| Dosage form | Injection |
| Strength | 200 mEq/100 mL (2 mEq/mL) |
| Status | Current |
| Therapeutic category | Endocrinology/Metabolism Gastroenterology Pediatric Total Parenteral Nutrition |
| Package NDCs | 0409-3299-25 |
| First posted | Feb 3, 2016 |
| Last updated | Apr 11, 2025 |
At a glance
- 1–9 Package NDCs affected
- 10–99 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: